228 related articles for article (PubMed ID: 31949258)
1. Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.
Xiong C; Wen Y; Zhao J; Yin D; Xu L; Chelariu-Raicu A; Yao C; Leng X; Liu J; Chaudhari RR; Zhang S; Sood AK; Li C
Sci Rep; 2020 Jan; 10(1):520. PubMed ID: 31949258
[TBL] [Abstract][Full Text] [Related]
2. A synthetic bivalent peptide ligand of EphB4 with potent agonistic activity.
Fan T; Liang B; Nie L; Wang J; Zhang H; Ciechanover A; Xu Y; An J; Huang Z
Eur J Med Chem; 2022 Dec; 244():114804. PubMed ID: 36208510
[TBL] [Abstract][Full Text] [Related]
3. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
[TBL] [Abstract][Full Text] [Related]
5. PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity.
Noberini R; Mitra S; Salvucci O; Valencia F; Duggineni S; Prigozhina N; Wei K; Tosato G; Huang Z; Pasquale EB
PLoS One; 2011; 6(12):e28611. PubMed ID: 22194865
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic interference with EphrinB2 signalling inhibits oxygen-induced angioproliferative retinopathy.
Ehlken C; Martin G; Lange C; Gogaki EG; Fiedler U; Schaffner F; Hansen LL; Augustin HG; Agostini HT
Acta Ophthalmol; 2011 Feb; 89(1):82-90. PubMed ID: 19764912
[TBL] [Abstract][Full Text] [Related]
7. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.
Kertesz N; Krasnoperov V; Reddy R; Leshanski L; Kumar SR; Zozulya S; Gill PS
Blood; 2006 Mar; 107(6):2330-8. PubMed ID: 16322467
[TBL] [Abstract][Full Text] [Related]
8. Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
Piffko A; Broggini T; Harms C; Adams RH; Vajkoczy P; Czabanka M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360793
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers.
Bhatia S; Oweida A; Lennon S; Darragh LB; Milner D; Phan AV; Mueller AC; Van Court B; Raben D; Serkova NJ; Wang XJ; Jimeno A; Clambey ET; Pasquale EB; Karam SD
Cancer Res; 2019 May; 79(10):2722-2735. PubMed ID: 30894369
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis.
Sasine JP; Kozlova NY; Valicente L; Dukov J; Tran DH; Himburg HA; Kumar S; Khorsandi S; Chan A; Grohe S; Li M; Kan J; Sehl ME; Schiller GJ; Reinhardt B; Singh BK; Ho R; Yue P; Pasquale EB; Chute JP
Cancer Res; 2024 Mar; 84(6):919-934. PubMed ID: 38231476
[TBL] [Abstract][Full Text] [Related]
11. Ligand-dependent EphB4 activation serves as an anchoring signal in glioma cells.
Kawahara Y; Furuta T; Sabit H; Tamai S; Dong Y; Jiapaer S; Zhang J; Zhang G; Oishi M; Miyashita K; Hayashi Y; Nakada M
Cancer Lett; 2019 May; 449():56-65. PubMed ID: 30776480
[TBL] [Abstract][Full Text] [Related]
12. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.
Noren NK; Yang NY; Silldorff M; Mutyala R; Pasquale EB
Biochem J; 2009 Aug; 422(3):433-42. PubMed ID: 19552627
[TBL] [Abstract][Full Text] [Related]
13. Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
Liersch-Löhn B; Slavova N; Buhr HJ; Bennani-Baiti IM
Int J Cancer; 2016 Mar; 138(5):1220-31. PubMed ID: 26414866
[TBL] [Abstract][Full Text] [Related]
14. Ephrin‑B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis‑free survival in breast cancer.
Magic Z; Sandström J; Perez-Tenorio G
Int J Oncol; 2019 Dec; 55(6):1275-1286. PubMed ID: 31638179
[TBL] [Abstract][Full Text] [Related]
15. Ephrin-B2 reverse signaling is required for axon pathfinding and cardiac valve formation but not early vascular development.
Cowan CA; Yokoyama N; Saxena A; Chumley MJ; Silvany RE; Baker LA; Srivastava D; Henkemeyer M
Dev Biol; 2004 Jul; 271(2):263-71. PubMed ID: 15223333
[TBL] [Abstract][Full Text] [Related]
16. EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma.
Randolph ME; Cleary MM; Bajwa Z; Svalina MN; Young MC; Mansoor A; Kaur P; Bult CJ; Goros MW; Michalek JE; Xiang S; Keck J; Krasnoperov V; Gill P; Keller C
PLoS One; 2017; 12(8):e0183161. PubMed ID: 28817624
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination.
Lennon S; Oweida A; Milner D; Phan AV; Bhatia S; Van Court B; Darragh L; Mueller AC; Raben D; Martínez-Torrecuadrada JL; Pitts TM; Somerset H; Jordan KR; Hansen KC; Williams J; Messersmith WA; Schulick RD; Owens P; Goodman KA; Karam SD
Clin Cancer Res; 2019 Jun; 25(11):3352-3365. PubMed ID: 30944125
[TBL] [Abstract][Full Text] [Related]
18. Dynamic changes occur in patterns of endometrial EFNB2/EPHB4 expression during the period of spiral arterial modification in mice.
Zhang J; Dong H; Wang B; Zhu S; Croy BA
Biol Reprod; 2008 Sep; 79(3):450-8. PubMed ID: 18463357
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.
Bhatia S; Sharma J; Bukkapatnam S; Oweida A; Lennon S; Phan A; Milner D; Uyanga N; Jimeno A; Raben D; Somerset H; Heasley L; Karam SD
Clin Cancer Res; 2018 Sep; 24(18):4539-4550. PubMed ID: 29848571
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
